University of Missouri researchers discovered that losartan, a blood pressure drug, enhances AML chemotherapy response and reduces heart toxicity.
University of Missouri researchers found that losartan, a common blood pressure drug, may make acute myeloid leukemia (AML) more responsive to chemotherapy while also protecting the heart from chemo-induced toxicity. Losartan inhibits AGTR1, a receptor responsible for cell reproduction overabundant in leukemia patients, disrupting cancer growth and slowing its development. This targeted gene therapy could benefit adult AML patients at higher risk of cardiac damage due to chemotherapy.
June 27, 2024
3 Articles